Kiniksa Pharmaceuticals, Ltd.
KNSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,858,109 | $2,032,057 | $1,613,493 | $1,430,470 |
| - Cash | $174,858 | $192,037 | $157,132 | $183,581 |
| + Debt | $9,718 | $9,765 | $9,915 | $9,855 |
| Enterprise Value | $2,692,969 | $1,849,785 | $1,466,276 | $1,256,744 |
| Revenue | $180,855 | $156,797 | $137,785 | $122,536 |
| % Growth | 15.3% | 13.8% | 12.4% | – |
| Gross Profit | $97,264 | $85,763 | $76,127 | $56,363 |
| % Margin | 53.8% | 54.7% | 55.3% | 46% |
| EBITDA | $27,541 | $20,518 | $13,617 | -$16,579 |
| % Margin | 15.2% | 13.1% | 9.9% | -13.5% |
| Net Income | $18,435 | $17,832 | $8,539 | -$8,888 |
| % Margin | 10.2% | 11.4% | 6.2% | -7.3% |
| EPS Diluted | 0.23 | 0.23 | 0.11 | -0.12 |
| % Growth | 0% | 109.1% | 191.7% | – |
| Operating Cash Flow | $33,677 | $28,090 | $22,324 | $18,770 |
| Capital Expenditures | -$671 | -$165 | -$99 | -$193 |
| Free Cash Flow | $33,006 | $27,925 | $22,225 | $18,577 |